Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16413340 | 1.00 | ELANE (0.43) | ELANECYP3A4DDB1CRBNBIRC2 | |
| SCHEMBL8038460 | 0.90 | ELANE (0.46) | ELANEDDB1CRBNBIRC2 | |
| SCHEMBL15213352 | 0.90 | ELANE (0.37) | ELANECYP3A4BIRC2CYP19A1 | |
| SCHEMBL16318662 | 0.90 | ELANE (0.37) | ELANECYP3A4BIRC2CYP19A1 | |
| SCHEMBL12726041 | 0.89 | ELANE (0.46) | ELANECYP3A4DDB1CRBNBIRC2 | |
| SCHEMBL4408069 | 0.89 | ELANE (0.52) | ELANEBIRC2 | |
| SCHEMBL13594509 | 0.89 | ELANE (0.52) | ELANEBIRC2 | |
| SCHEMBL2743892 | 0.88 | KLK5 (0.34) | ELANEDDB1CRBNCYP19A1 | |
| SCHEMBL3244648 | 0.88 | ELANE (0.35) | ELANEBIRC2CYP19A1 | |
| SCHEMBL2744255 | 0.88 | HDAC8 (0.38) | ELANEDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321809-B2 | Macrocyclic compounds for suppressing replication of hepatitis C virus | GINKGO PHARAMA CO., LTD. (CN) | 2016-04-26 | — | — | US | disclosed |
| US-9321809-B2 | Macrocyclic compounds for suppressing replication of hepatitis C virus | GINKGO PHARAMA CO., LTD. (CN) | 2016-04-26 | — | — | US | disclosed |
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2015-01-29 | — | — | US | disclosed |
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2015-01-29 | — | — | US | disclosed |
| EP-2816054-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120371-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | 银杏树药业(苏州)有限公司 (CN) | 2013-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | HCCS, HAVCR2, EIF2AK2 | ELANE 641/4885CYP3A4 469/4885DDB1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.